In an interdisciplinary team at Washington University, we are proposing ways to improve the FDA approval process. Our first editorial was recently published.

Michele Boldrin and S. J. Swamidass. A new bargain for drug approvals. Wall Street Journal, July 2011.

In the September 2010 issue of Science this article was cited in the lead editorial, Rethinking Clinical Trials.

Excellent commentary on our proposal can be found at Marginal Revolution, The Incidental Economist, Something Not Unlike Research, the National Review Online, and SeekerBlog.